NET Recovery has received FDA Breakthrough Device Designation for its innovative device aimed at treating stimulant use disorder, a critical milestone for addiction treatment.

SonoClear AS has successfully completed clinical enrollment for its innovative SonoClear System aimed at enhancing neurosurgical procedures, paving the way for FDA submission.

Armata Pharmaceuticals celebrates a significant milestone with the FDA granting Breakthrough Therapy designation to AP-SA02, revolutionizing bacterial infection treatment.

Johnson & Johnson’s RYBREVANT FASPRO™ has received Breakthrough Therapy Designation from the FDA for the treatment of advanced head and neck cancer, promising new hope for patients.

CND Life Sciences has received the FDA's Breakthrough Device Designation for its Syn-One Test, aiding in the diagnosis of synucleinopathies in patients.

PatenSee has been granted FDA's Breakthrough Device Designation for its non-contact vascular access management technology, promising enhanced kidney care.

Restore Medical Ltd. has successfully raised $23 million in financing to propel its groundbreaking transcatheter therapy for heart failure, aiming to enhance patient outcomes worldwide.

SonoClear AS has received FDA breakthrough designation for its SonoClear® System, enhancing imaging during brain tumor surgery. This breakthrough aims to improve surgical outcomes.

CytoSorbents Corporation has reported its Q1 2025 financial results, highlighting revenue changes and strategic advancements in their business operations.

Phantom Neuro achieves FDA Breakthrough Device and TAP Designations, reinforcing its position in neurotechnology for intuitive mobility solutions.

OrthoPreserve's innovative meniscus implant, Defender, gains FDA Breakthrough Device Designation, marking a significant advancement in knee pain management.